This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...
Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic ...
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...
ECMO or ventilator use was the most significant predictor of mortality in patients undergoing lung transplant for idiopathic ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.
IPF is a rare progressive fibrosing interstitial lung disease with symptoms that include breathing difficulty, dry and persistent cough, chest discomfort and fatigue. The randomized, double-blind, ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
A panel of experts, including Dr Rohit Aggarwal, Principal Investigator of the decentralized Myositis Interstitial Lung ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
The FIBRONEER™-IPF trial is the largest trial in idiopathic pulmonary fibrosis (IPF ... research activities to develop more options for one of the most common interstitial lung diseases.” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback